NEW YORK – Cancer detection firm Grail said Tuesday that it has entered an agreement with Quest Diagnostics for phlebotomy services in support of Galleri, Grail's multi-cancer early detection blood test.
Under the agreement, Secaucus, New Jersey-based Quest will use its phlebotomy network, which comprises roughly 2,200 patient service centers and 5,000 mobile phlebotomists, to help Menlo Park, California-based Grail with specimen collection when it launches the test this year.